Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 227-232

  Nisticò, Cecilia ^a   Bria, Emilio ^a   Cuppone, Federica ^a   Carpino, Armando ^a   Ferretti, Gianluigi ^a   Vitelli, Gaetano ^a   Sperduti, Isabella ^a   Calabretta, Francesca ^a   Toglia, Giuseppe ^a   Tomao, Silverio ^a   Cognetti, Francesco ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cardiotoxicity; Epirubicin; Myoglobin; Paclitaxel; Troponin; Weekly

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; ENZYME; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYOGLOBIN; PACLITAXEL; TROPONIN T;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD FLOW VELOCITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; EYE DISEASE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPENIA;; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYOGLOBIN; PACLITAXEL; STROKE VOLUME; TROPONIN T;

EID: 33845689864     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328011335e     Document Type: Article

References (34)

1. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994; 93:433-443.
2. Lipshultz SE, Sanders SP, Colan SD, Goorin AM, Sallan SE, Krischer J. The anthracycline cardiotoxicity debate. Pediatrics 1994; 94:781-782.
3. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
4. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005;16:798-804.
5. Nisticò C, Garufi C, Barni S, Frontini L, Gallà DA, Giannarelli D, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999; 10:937-942.
6. Bria E, Giannarelli D, Felici A, Peters WP, Nistico C, Vanni B, et al. Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer: pooled analysis of 2805 patients. Cancer 2005; 103:672-679.
7. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995a; 13:2688-2699.
8. Gehl J, Boesgard M, Paaske T, Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7:687-693.
9. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, et al. A randomised comparison of single-agent doxorubicin and epirubicin as firstline cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991; 9:2148-2152.
10. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, et al. Dose-finding and pharmacokinetics of epirubicin and paclitaxel over 3 h: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15:2510-2517.
11. Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, DiPaolo A, et al. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol 2002; 53:508-518.
12. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999; 17:3596-3602.
13. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16:3502-3508.
14. Nistico C, Garufi C, Milella M, D'Ottavio AM, Vaccaro A, Fabi A, et al. Weekly epirubicin plus lonidamine in advanced breast carcinoma. Breast Cancer Res Treat 1999; 56:233-237.
15. Nistico C, Garufi C, Barni S, Frontini L, Galla DA, Giannarelli D, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999; 10:937-942.
16. Grasselli G, Vigano L, Capri G, Locatelli A, Tarenzi E, Spreafico C, et al. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 2001; 19:2222-2231.
17. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004; 279:8290-8299.
18. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62:865-872.
19. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, et al. Correlation between serum levels of cardiac troponin T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237-2243.
20. Lewis W, Gonzalez B. Anthracycline effects on actin and actin-containing thin filaments in cultured neonatal rat myocardial cells. Lab Invest 1986; 54:416-423.
21. Molinari A, Calcabrini A, Crateri P, Arancia G. Interaction of anthracyclinic antibiotics with cytoskeletal components of cultured carcinoma cells (CG5). Exp Mol Pathol 1990; 53:11-33.
22. Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 67:1360-1367.
23. Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83:902-912.
24. Kragten JA, Hermens WT, van Dieijen-Visser MP. Cardiac troponin T release into plasma after acute myocardial infarction: only fractional recovery compared with enzymes. Ann Clin Biochem 1996; 33:314-323.
25. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96:2641-2648.
26. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
27. Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol 1998; 25:552-537.
28. Missov E, Pau B, Calzolan C. Increased circulating levels of cardiac troponin I in anthracycline-treated patients [abstract]. Circulation 1996; 94:(Suppl I):732.
29. Raderer M, Kornek G, Weinlander G, Kastner J. Serum troponin T levels in adults undergoing anthracycline therapy. J Nat Cancer Inst 1997; 89:171.
30. Missov E, Calzolari C, Pau B. Increased levels of cardiac troponin I in cancer patients [abstract]. J Am Coll Cardiol 1997; 129:321a.
31. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13:710-715.
32. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96:2641-2648.
33. Fink FM, Genser N, Fink C, Falk M, Mair J, Maurer-Dengg K, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 25:185-189.
34. Kremer LCM, Bastiaansen BAJ, Offringa M, Lam J, van Straalen JP, de Winter RJ, et al. Troponin T in the first 24 h after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002; 38:686-689.